Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville
Maryland
20850
United States
Tel: 301-309-8504
Fax: 301-309-8512
Website: http://www.hgsi.com/
About Human Genome Sciences, Inc.
Human Genome Sciences (HGS) is located in the Washington, DC metro area, and was founded in 1992 with the goal of creating a global biopharmaceutical company to discover, develop, manufacture, and market gene-based drugs to address unmet medical needs. We have a significant product pipeline with seven products in clinical development, including drugs to treat hepatitis C, lupus and other autoimmune diseases, anthrax exposure, and cancer. In recent years, we have progressed toward becoming a late stage development and commercialization company, and we have recently started Phase 3 trials for three of our key development programs.HGS is developing an innovative new treatment for systemic lupus erythematosus (SLE), which would be the first new treatment for lupus in nearly 40 years. This product, belimumab, is being co-developed and commercialized with Glaxo SmithKline. We are also developing a long-acting interferon alpha, Albuferon, for Hepatitis C, along with Novartis. HGS has also been awarded a two-phase contract with US government to supply them with ABthrax, a monoclonal antibody treatment for anthrax, for the Strategic National Stockpile, which we expect to deliver in 2008.
At HGS, people are the key to our success. We share a passion for scientific and business innovation, creating unique opportunities to contribute to the commercialization phase of our products. At HGS, you will have opportunities to learn and grow, interacting with talent of the highest caliber, and you will be supported by a culture committed to employee and leadership development. We offer a competitive salary and benefits package. HGS is an Equal Opportunity Employer EOE/AA M/F/D/V.
Please visit www.hgsi.com for further information on our company.
349 articles about Human Genome Sciences, Inc.
-
Cell Medica Appoints Julia P. Gregory as Non-Executive Director and Audit Chair
6/13/2018
Cell Medica today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
-
Anthrax Drug Brings $334 Million to Pentagon Advisor's Biotech Firm - Human Genome Sciences, Inc.
5/20/2013
-
Human Genome Sciences, Inc. to Lay Off 97 Workers
10/19/2012
-
4-Antibody AG Receives Additional Milestone Payments From Human Genome Sciences, Inc.
10/8/2012
-
Human Genome Sciences, Inc. to Cut 114 Positions
9/6/2012
-
GlaxoSmithKline Completes $3.6 Billion Takeover of Human Genome Sciences, Inc.
8/6/2012
-
Exclusive: Human Genome Sciences, Inc. Rejected Amgen's $7 Billion Bid in 2010
7/27/2012
-
3 Lessons From GlaxoSmithKline's Purchase of Human Genome Sciences, Inc.
7/17/2012
-
GlaxoSmithKline Clinches Deal to Buy Human Genome Sciences, Inc. for $2.8 Billion
7/16/2012
-
Human Genome Sciences, Inc. Release: Survey Shows the Burden of Lupus on Work and Wallet
7/11/2012
-
FYI From Human Genome Sciences, Inc.: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes
7/11/2012
-
Human Genome Sciences, Inc. Announces Resubmission of Raxibacumab BLA to FDA
7/10/2012
-
Will Celgene Bid for Human Genome Sciences, Inc.?
7/9/2012
-
GlaxoSmithKline Lines Up Nominees for Human Genome Sciences, Inc. Board
7/6/2012
-
GlaxoSmithKline Sets Time of Tender Offer to Buy Human Genome Sciences, Inc. to July 20
6/29/2012
-
Human Genome Sciences, Inc. Sets Deadline for Buyout Offers
6/15/2012
-
MedImmune CEO Peter Greenleaf, Human Genome Sciences, Inc. CEO Tom Watkins, Montgomery County, Maryland Executive Isiah Leggett Come Together in the Maryland Pavilion at the 2012 Biotechnology Industry Organization (BIO)
6/14/2012
-
GlaxoSmithKline Adds 3 Weeks for Human Genome Sciences, Inc. Tender
6/8/2012
-
Human Genome Sciences, Inc. Announces Multiple Abstracts Related to BENLYSTA® and Systemic Lupus Erythematosus to be Presented at the 2012 EULAR Annual European Congress of Rheumatology
6/6/2012
-
Human Genome Sciences, Inc. Response to GlaxoSmithKline Press Release
6/4/2012